Please login to the form below

Not currently logged in
Email:
Password:

Dr Georg Buchner joins Silence Therapeutics

He assumes a business development role at the London-based biotech

London-based biotech Silence Therapeutics has appointed Dr Georg Buchner VP, business development.

He was formerly VP of Corporate & Business Development at Novacta Biosystems and prior to that served as business development director at Haptogen. During that time he was instrumental in the sale of the Haptogen business to Wyeth, now part of Pfizer, in 2007

At Silence Georg will work with Tony Sedgwick, who was appointed chief business officer in September, as part of the company's strategy to continue to broaden its collaborations with global pharmaceutical and biotechnology companies.

Silence's CEO Thomas Christély said: "We are pleased to welcome Dr Georg Buchner to Silence. Georg has a strong track record in business development and his experience will strengthen our growing business development team as we seek to expand our increasing list of corporate partnerships.”

10th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera

Our higher purpose is to deliver better communication to increase and speed up the ability of patients to access better...

Latest intelligence

Emotional Intelligence and Blended Learning in Healthcare
...
Running
A marathon and a sprint
Customer experience is a long-distance race and with pharma late out of the blocks, companies need to put their foot down if they want to compete...
5 tactics to master Market Access
Is it time to rethink your game plan? To succeed at Market Access, follow these 5 tactics:...

Infographics